AnnJi Pharmaceutical News
Dedicated to New Drug Development in Dermatology & Neurology
最新消息
AJ201第一筆簽約金與股票已依約全額收足
安基生技與那斯達克上市公司Avenue於三月初簽署罕病小分子新藥AJ201歐洲、美國及以色列獨家研發合作與授權合約，Avenue依據雙方簽立之專利授權合約已經依約準時支付第一階段簽約金200萬美元(約6000萬台幣)，並將Avenue發行之15%股票(計831,618股)依約登錄至安基名下持有。依據此授權合約，下一筆簽約金將於第三季前依約支付。 安基的AJ201為治療罕見遺傳性疾病甘迺迪式症之fi
Yahoo Finance: AnnJi Pharmaceutical Announced Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Kennedy’s Disease Treatment
TAIPEI, March 14, 2023 /PRNewswire/ — AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development an
朝日新聞：AnnJi Pharmaceuticalは、ケネディ病治療用のファースト・イン・クラス臨床資産AJ201の開発・商品化でAvenue Therapeuticsとのライセンス契約を発表
【台北2023年3月14日PRNewswire＝共同通信JBN】AnnJi Pharmaceutical Co.（AnnJi）は、Avenue Therapeutics Inc.（Avenue、NASDAQ：ATXI）と、米国、カナダ、欧州連合、英国およびイスラエルにおける、ケネディ病としても知られる球脊髄性筋萎縮症（SBMA）用のAJ201の開発・商品化に関する独占ライセンス契約を締結しました。
騰訊網：安基生技新药 AJ201罕病新药獲国际授权金逾2.5亿美金
台北2023年3月14日 — 台湾生技产业再创国际授权佳绩-安基生技新药（安基）于日前宣布，与美国那斯达克上市生技新药公司Avenue Therapeutics Inc. (NASDAQ:ATXI)签订AJ201罕见疾病-肯尼迪氏症小分子新药欧美专属许可协议。授权条件除了签约金、里程碑金等合计最高可达2.5亿美金的授权金外，安基未来还可再以超越两位数的分润百分比就销售额抽成分润。此次是
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy’s Disease
AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S., Ca
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease also known as Kennedy’s Disease which currently has no FDA approved therapy
Taiwan’s leading new drug developer in dermatology & neurology
Translation and development of new chemical entities from lead optimization, candidate selection to clinical proof-of-concept
